Victoza also has a black box cancer warning so there will be patients leery about taking it.
You are assuming Bydureon will not get blackbox warning.
It took a long delay for Victoza getting approved. During Victoza review, FDA requested lots of information from Byetta/Bydureon as well to see this class drug effect - AMLN didn't know what was for at that time until Victoza advisory panel. So FDA knows these drugs really well.
All I am saying is there is no pressing reason to approve Bydureon RIGHT NOW. I still think it will likely get approved eventually. From once/twice a day to weekly is a big leap forward in diabetes drug development. FDA treated this cautiously as it is warranted in my opinion.
I know diabetes market quite well. I had been a NVO shareholders for a while (not right now, sold a month too early). I believe diabetes market will explode in the future. Even small diabetes drug developer like BIOD, HALO with differentiated products will have good future.
Market Data 
Markets 
AI
